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Objectives: To understand the illness experience of patients with chronic hep-
atitis C participating in clinical trials in the sociocultural context of Korea in an
in-depth and comprehensive manner.
Methods: A focused ethnography approach was used to discover the pattern of illness
experience of patients with chronic hepatitis C in the cultural background of Korea.
Interviews were conducted with 11 patients with chronic hepatitis C participating in
clinical trials and the collected data were analyzed with the domain analysis, tax-
onomical analysis, componential analysis, and theme analysis proposed by Spradley.
Results: With the cultural theme of “less-known illness, less-familiar illness,” four
categories were derived: “my illness discovered by accident,” “shaken life,” “scary
but inevitable treatment method,” and “precious life that can’t be wasted,” along
with 12 properties.
Conclusion: Public campaigns or education programs are needed to meet the needs
for information on the disease for patients with chronic hepatitis C participating in
clinical trials and help the general public acquire knowledge or change view on this
disease.1. Introduction
Hepatitis C is a disease in the liver caused by hepa-
titis C virus (HCV), with estimates suggesting about 150
million people being infected globally (i.e., 1.6% of the
population) [1]. Approximately 80% of the patients with
hepatitis become chronic [2], developing complications,
such as liver cirrhosis, terminal liver diseases, or hepa-
tocellular carcinoma over a few years or decades [3]. In
Korea, the prevalence of HCV representing the entire
population is not yet known [4], but approximately
10e15% of cases with liver cirrhosis or hepatocellularnaver.com (E. Park).
ase Control and Prevention.
reativecommons.org/licenscarcinoma are estimated to be caused by chronic hepa-
titis C [5].
HCV is parenterally transmitted, and its major routes
of infection are transfusion of blood or blood products
contaminated by HCV; organ transplant; intravenous
drug abuse including narcotic drugs, unsafe injections, or
medical procedures; and sexual contact with HCV car-
riers [6]. In particular, it is known that the reuse of
contaminated needles, endoscopies, dental treatments and
piercing, acupuncture or tattooing without appropriate
sterilization are the risk factors of HCV infection in
countries with the high prevalence of HCV [6].Published by Elsevier Korea LLC. This is an open access article
es/by-nc-nd/4.0/).
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devaluation or stigma [7], they negatively affect the
physical and psychosocial health of patients [8]. A
previous study found that patients with chronic hepatitis
C experience shame, decreased self-esteem, fear,
depression, and isolation [9]. It was also revealed that
patients with hepatitis C have a sense of guilt where they
hide the disease or attribute it to themselves being
careless due to the view that patients with chronic
hepatitis C are considered illegal drug abusers [9].
Since 1989, when HCV was first discovered [10],
treatments for chronic hepatitis C have been rapidly
developed and many direct-acting antivirals are waiting
for approval, to replace the standard combination treat-
ment of peginterferon and ribavirin, which has shown
many side effects [11]. For these direct-acting antiviral
products to be approved by the Ministry of Food and
Drug Safety, a clinical trial needs to be conducted on
human beings to confirm the effectiveness and safety of
the new drugs [12]. Therefore, those who participate in
clinical trials may feel scared and anxious due to the
possible side effects or uncertainties from the unknown
drugs [13], and experience emotional disorders,
decreased self-esteem, and powerlessness [14]. For these
reasons, patients with chronic hepatitis C participating
in clinical trials need to be provided with the appropriate
knowledge and information on the clinical trial(s), and
an understanding should be made on their experience in
illness treatment to support their emotions.
In other countries, studies on the stigma, treatment
experience, and illness experience of patients with chronic
hepatitis C are actively underway [9,15e17]. In Korea,
however, only a very few studies on the illness experience
of hepatitis B, among other chronic liver diseases, have
been carried out [18,19], and few studies have been con-
ducted on patients with chronic hepatitis C [20].
The illness experience of individual patients varies
depending on individuals, families, and societies; it is
attributable to the social, cultural, and environmental
context of the group to which they belong. A focused
ethnography can be used when a researcher focuses on a
special aspect rather than a general aspect and is familiarTable 1. General characteristics of participants.
No. Sex Age (y) Educational level Route of in
1 Female 69 Elementary school Acupuncture, T
2 Female 60 High school Acupuncture
3 Male 45 High school Drug, Tattoo
4 Male 59 High school Acupuncture
5 Female 60 Middle school Piercing, Denta
6 Male 57 High school Drugs
7 Male 49 High school Drug, Tattoo
8 Female 63 Elementary school Acupuncture
9 Male 56 High school Acupuncture, T
10 Female 64 Elementary school Tattoo
11 Male 59 High school Drugwith the study environment [21]. This study attempted
to understand the illness experience of Korean patients
with chronic hepatitis C participating in clinical trials in
the sociocultural context in an in-depth and compre-
hensive manner.2. Materials and methods
2.1. Research design
This is a focused ethnography to explore the illness
experience of Korean patients with chronic hepatitis C
who participate in clinical trials in the sociocultural
context. The first author of this study was in constant
contact with patients with chronic hepatitis C in the
Department of Gastroenterology. The gastroenterology
outpatient clinic is a place reflecting the culture that can
affect the experience of patients and is of help for exploring
the culture related to the illness experience of patients with
chronic hepatitis C participating in clinical trials. The
gastroenterology outpatient clinic for this study is located
at a tertiary hospital in a metropolitan city in Korea.
2.2. Participants
We included 11 adults who intended to participate in
the study after reading the notice for recruiting with
regard to the illness experience of patients with chronic
hepatitis C participating in clinical trials (Table 1).
2.3. Data collection
Data were collected through in-depth interviews and
participatory observations. During the interviews, the
responses and attitudes of participants and the emotion
and feeling of the interviewer were recorded in detail.
In-depth interviews were conducted two to three times
per participant with each interview taking 1e1.5 hours
in a meeting room of the gastroenterology department or
a tea house, depending on the preference of participants.
Participatory observations were made at the level of
observation as participants. The observations as partic-
ipants were performed in such a way that the author as a
medical professional collected data while providingfection Detection time (years ago) Occupation
ransfusion 26 Full-time worker
20 House wife
11 Self employment
10 Religious man
l treatment 2 House wife
15 Self employment
4 Crewman
3 House wife
attoo 12 Self employment
3 House wife
15 Self employment
396 H.-J. Cho, E. Parkconsultations and treatment processes by responding to
the demands made by participants.
2.4. Ethical issue
The study was approved by the Institutional Review
Board (IRB No. 1041386-20150826-HR-008-03), and
was conducted in accordance with the principles of the
Declaration of Helsinki. Before data collection, the
participants provided signed informed consent. Their
rights and privacy were protected throughout the study.
2.5. Data analysis
Data were analyzed with the domain analysis, tax-
onomical analysis, componential analysis, and theme
analysis proposed by Spradley [22]. In the first step, the
recorded interviews by participants were transcribed. An
overall picture for the treatment of patients with chronic
hepatitis Cwas drawn through this step. In the second step,
a categorization was made by planning the questions for
the next steps or the focuses of observations and consid-
ering the semantic relations of the explored data based on
the domain analysis. In the third step, a componential
analysis was performed, in which the properties of the
categories were systematically derived by classifying the
data into similar meanings. In the fourth step, the process
of the theme analysis was carried out, where the culture
theme that reappeared both implicitly and explicitly in the
treatment processes for patients with chronic hepatitis C
and repeatedly appeared in the culture was discovered.3. Results
The results of the analysis using a focused ethnog-
raphy showed that four categories and 12 propertiesTable 2. Cultural theme, categories, and properties.
Cultural theme (1) Categories (4)
Less known illness,
less-familiar illness
My illness discovered by accid
Unexpected responses from &
ignorance of people around me
Shaken life
Alert against indiscreet supplem
& alternative therapies
Scary but inevitable treatment m
Precious life that can’t be wastwere derived with the cultural theme of “less-known
illness, less-familiar illness” (Table 2). The properties in
each category are as follows:
3.1. My illness discovered by accident
3.1.1. Uncertainty over the incurable disease
I heard that there would be no cure at all, and I need
to sleep well, try not to gain weight and not to be
picky about food. [Participant 1]
I was scared because there was no medication for the
disease. I seemed to get more addicted to drugs
because there is no medication for the disease.
[Participant 6]
3.1.2. Regret over the reckless life in the past
I had led a reckless life until my late thirties. I
couldn’t take care of my health at the time. [Partic-
ipant 3]
I had repeatedly made up my mind to quit drugs, but I
kept failing. Even after I was arrested, I couldn’t stop
it. I was completely crazy. I was a psycho . really
insane. [Participant 6]
3.1.3. Unexpected responses from and ignorance
of people around me
A majority of people don’t know about hepatitis C
and hepatitis B. They might have heard about liver
cirrhosis, but hepatitis C. [Participant 6]Properties (16)
ent Uncertainty over the incurable disease
Regret over the reckless life in the past
Disappointment to medical staff who
did not explain properly
Fear for the development of the disease
entary
ethod Frustration from the side effects of
the existing standard treatments
Encouragement from people around me
A slowly developing hope in difficult time
ed Thorough medication compliance
Expectation for the removal of stigma
My intention to be totally changed
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call me a junkie in front of me because of my human
right. I carry a law book with me because I want to
sue them. Now, it is not acceptable to call someone a
junkie. [Participant 6]3.2. Shaken life
3.2.1. Disappointment to medical staff who did not
explain properly
To be honest, I was responsible for not doing my own
research, but the physicians who treated me did not
explain properly. If they explained the process and
development of my disease, I could know how serious
my disease was. They just showed me the chart in
English, and when I asked something, they only said
it would be OK. I thought I was OK because the
physicians told me that I would be OK. [Participant 9]
3.2.2. Fear for the development of the disease
Whenever I felt tired, even while washing dishes, I
thought I felt sick because of my hepatitis. I thought it
might be due to the elevated values from my test.
After the exam in March, I went for another exam
every month in May, June and July, because I was
concerned. [Participant 2]
3.2.3. Alert against indiscreet supplementary and
alternative therapies
I have never tried something that people say is good
for the liver. I have never taken Korean herbal
medicine. Someone suggested me take oriental raisin
tree tea, but I didn’t feel like taking it. If it were that
effective, why would not other people take it?
[Participant 1]
I found from the Internet that I must not take Korean
herb tea or raw food in particular. Since then, I
stopped eating raw fish due to the possible infection
from parasites, although I used to enjoy eating raw
fish. [Participant 7]3.3. Scary but inevitable method
3.3.1. Frustration from the side effects of the
existing standard treatments
When I first got the injection, I thought I would die. I
couldn’t do my work because I felt like my body was
burning. I was totally exhausted and almost dead
because of the terrible fever overnight. The next
morning, pain was gone, but I didn’t have appetite. I
lost 8 kg within a month. [Participant 7]In the beginning, I was treated with the Interferon
and Ribavirin combination. It was a 48-week treat-
ment course for 1 year, and I still clearly remember
that time. I had fever, body ache, including my four
limbs, headache, shortness of breath, which made my
walking hard, thinned hairs, lost weight, retching,
insomnia and depression. I endured all of those for
my treatment. [Participant 9]
3.3.2. Encouragement from people around me
My friend told me not to drink alcohol and just get
treatment. He was worried about the possibility of my
getting cirrhosis and ending up dead. He told that he
cared for me a lot next to his family and cried.
[Participant 1]
I learned from the TV that medication for hepatitis is
more effective than that for hepatitis B from a year
before. [Participant 8]
3.3.3. A slowly developing hope in difficult time
I haven’t been in the society for over 10 years
because I was in jail. I was insane. I can now focus a
little on my disease as there is treatment medication
available. I am not distracted now because I have a
job in a small company. Now, I think narcotic drugs
are not better than salt. They are useless. [Partici-
pant 6]
About three of my friends died of liver diseases. I was
scared and thought I needed to get treatment now. I
was also encouraged by the news that the new
medication is very effective. [Participant 11]3.4. Precious life that can’t be wasted
3.4.1. Thorough medication compliance
I think I am really lucky because I can get this
treatment after a long wait. It is like winning a lot-
tery. [Participant 11]
I don’t find the treatment process difficult. There is no
problem, but I skipped taking medication twice by
mistake. I am a little concerned that missing medi-
cation can result in a bad treatment result. Is it
possible to get two more pills for me? [Participant 2]
3.4.2. Expectation for the removal of stigma
Once I am cured, I can proudly say that I have been
suffering from hepatitis C and finally overcome all
the difficulties from the disease. [Participant 9]
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only infected through blood, people are a little hes-
itant about being near me. I want to be a leader in
changing such recognition. [Participant 9]
3.4.3. My intention to be totally changed
I can’t express it in words. There is no way to do that.
I want to spend the rest of my life for contributing to
something good. How can I waste this blessed life? I
am going to do something that can make people
happy. [Participant 8]4. Discussion
This study employed a focused ethnography
approach to derive psychological change and cultural
significance experienced by patients with hepatitis C,
which is not well-known in the sociocultural back-
ground of Korea, while they were participating in clin-
ical trials.
From this study, the cultural theme of “less-known
illness, less-familiar illness” was derived in the cultural
domain of the illness experience of Korean patients with
chronic hepatitis C. With this theme, four categories
were derived: “my illness discovered by accident,”
“shaken life,” “scary but inevitable treatment method,”
and “precious life that can’t be wasted,” along with the
semantic structure of 12 properties. Each category is
discussed in the following sections.
In the first category of “my illness discovered by
accident,” the major experience related to the diagnosis
of patients was found to include “uncertainty” and
“regret.” In addition, they experienced “a sense of
stigma” from people around them due to the lack of
awareness of hepatitis C. Hepatitis C is more chronic
than hepatitis B (5% vs. 50e80%) [23] and has a long
process of development without specific symptoms [24].
Therefore, the diagnosis of hepatitis C often causes
frustration to the patients, because they usually are
diagnosed during their regular check-ups without any
symptoms for a long time. In Korea, the combination
treatment of peginterferon and ribavirin had been a
standard treatment for hepatitis C until the revision of
the treatment guideline by the Korean Association for
the Study of the Liver in 2015 [25]. However, the
combination treatment had many side effects and
required a longer treatment period with a lower cure
rate. As a result, those who were diagnosed with chronic
hepatitis C felt uncertain due to the recognition that it is
not easy to be treated, and regretted for their behaviors
in the past. In addition, a social stigma was created
because of the lack of knowledge on the transmission
routes of hepatitis C by the general public. Therefore, an
education program needs to be developed for patients orthe general public on the causes, transmission routes,
and treatment methods of hepatitis C.
In the second category of “shaken life,” patients are
unhappy with the medical staff who did not properly
explain how to manage the disease after the diagnosis of
chronic hepatitis C, and afraid that the diseasemay rapidly
develop into cirrhosis or liver cancer. While they are
tempted to take the food that people say is beneficial for the
liver, they are also cautious of the food because it can
reduce the detoxicating function of the liver. The fact that
the participants of this study were not satisfied with the
explanation from the medical staff contrasts with the re-
sults reported by Sun and Ju [20], who noted that partici-
pants considered physicians and nurses their information
sources for chronic hepatitis C by 72.6% and 7.1%,
respectively. This indicates that although physicians
explain patients about chronic hepatitis C, they could not
explain enough for patients to be satisfied. Frazer et al [26]
also revealed that the level of knowledge on hepatitis C of
nurses is lower than that on other infectious diseases.
Therefore, education for hepatitis C customized to nurses
needs to be provided to the nurses who are in contact with
patientswith hepatitis C bydeveloping a programbased on
the knowledge level of nurses on hepatitis C.
In the third category of “scary but inevitable treat-
ment method,” patients were afraid of participating in
clinical trials in many aspects and felt frustrated due to
the side effect of the existing standard treatments, but
they became hopeful with the encouragement by people
around them and the results of clinical trials. Although
the treatment guideline for chronic hepatitis C was
revised in 2015 and took effect partly from 2016, pa-
tients are still concerned about the side effects because
the new guideline has not been proved on a long-term
basis. They, however, made their mind to participate
because they did not have other options. Therefore, a
program that can reduce the uneasiness of patients by
understanding their psychological mechanism needs to
be run before they participate in clinical trials.
In the fourth category of “precious life that can’t be
wasted,” they wanted to be reborn by thoroughly
ensuring medication compliance and to change the
recognition on the stigma in which people link the cause
of hepatitis C with the abuse of narcotic injection.
Considering the previous studies suggesting that medi-
cation compliance in chronic diseases is better when the
level of knowledge of patients is higher [27e28], an
effort needs to be made to enhance their knowledge on
chronic hepatitis C. To this end, the need of patients for
the domain they want to know should be first identified
and then a systematic education program should be
developed to address such need.
The results of this study will be the basic data to
develop an education program to improve the knowl-
edge of the general public or patients with chronic
hepatitis C on hepatitis C and prevent the transmission
of the disease.
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